BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Immunai and Teva Collaborate to Advance Clinical Trials in Oncology and Immunology

by Roman Kasianov   •   Nov. 14, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Startups & Deals   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Immunai, an AI-driven biotech company focused on mapping the human immune system, has partnered with Teva Pharmaceuticals in a multi-year collaboration aimed at improving clinical trial outcomes for oncology and immunology therapies.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

The collaboration will use Immunai’s proprietary immune cell atlas, AMICA, and its AI-powered Immunodynamics Engine (IDE) to enhance clinical decision-making. This tech will help deepen the understanding of drug mechanisms of action, optimize dose selection, and analyze biomarkers to improve trial success rates and patient outcomes.

Briefly, the AMICA platform—Annotated Multi-Omic Immune Cell Atlas—is reportedly the world’s largest single-cell immune knowledge base. It includes tens of millions of cells mapped across hundreds of disease settings and integrates over 5,000 studies, including more than 350 single-cell investigations. AMICA encompasses data on over 80 immune cell types, spanning 500 diseases, with insights derived from more than 100,000 patient samples. This resource powers the IDE, which combines functional genomics and advanced AI to uncover therapeutic biomarkers, validate hypotheses, and identify patient subgroups for clinical trials.

Noam Solomon, Ph.D., CEO of Immunai:

“Bringing a drug to market is inherently challenging, time-consuming, and costly. Through our partnership with Teva, we are eager to utilize our AI-based engine to streamline this process and help deliver new therapies to patients.”

Eran Harary, Senior Vice President and Global Head of Specialty R&D at Teva Pharmaceuticals:

“Partnering with Immunai enables us to leverage AI solutions that will enhance our research and development strategy. This collaboration will provide important insights into patient responses and treatment mechanisms, allowing us to optimize our clinical trials and improve outcomes for patients.”

Looking ahead, the partnership could expand to include broader areas of Teva’s research and development portfolio. Both companies emphasize their commitment to using innovative technology to bring faster, more effective solutions to patients.

Topics: Startups & Deals   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.